Cardiotoxicity of breast cancer chemotherapy.

Journal

Cardiology in review

ISSN: 1538-4683

Titre abrégé: Cardiol Rev

Pays: United States

ID NLM: 9304686

Informations de publication

Date de publication:
04 Sep 2023

Historique:

medline: 4 9 2023

pubmed: 4 9 2023

entrez: 4 9 2023

Statut: aheadofprint

Résumé

Breast cancer is one of the leading causes of malignancy affecting women in the United States. Although many effective treatments are available, most come with notable side effects that providers and patients must take into consideration. Various classes of chemotherapeutic agents, including anthracyclines and human epidermal growth factor receptor-2 antagonists, are known to be toxic to myocardial tissue. In this review article, we discuss what is reported in the literature regarding the cardiotoxicity of these agents as well as how to monitor and prevent cardiac injury and dysfunction.

Identifiants

DOI: 10.1097/CRD.0000000000000589 PMID: 37665235

pubmed: 37665235

doi: 10.1097/CRD.0000000000000589

pii: 00045415-990000000-00148

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Déclaration de conflit d'intérêts

Disclosure: The authors have no conflicts of interest to report.

Références

Shah AN, Gradishar WJ. “Adjuvant anthracyclines in breast cancer: what is their role?” Oncologist. 2018;23:1153–1161.

Bhagat A, Kleinerman ES. “Anthracycline-induced cardiotoxicity: causes, mechanisms, and prevention.” Adv Exp Med Biol. 2020;1257:181–192.

Zhang S, Liu X, Bawa-Khalfe T, et al. “Identification of the molecular basis of doxorubicin-induced cardiotoxicity.” Nat Med. 2012;18:1639–1642.

Alexander J, Dainiak N, Berger HJ, et al. “Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography.” Engl J Med. 2010;300:278–283.

Choi BW, Berger HJ, Schwartz PE, et al. “Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance.” Am Heart J. 1983;106:638–643.

Schwartz RG, McKenzie WB, Alexander J, et al. “Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: seven-year experience using serial radionuclide angiocardiography.” Am J Med. 1987;82:1109–1118.

Lyon AR, López-Fernández T, Couch LS, et al.; ESC Scientific Document Group. “2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).” Eur Heart J. 2022;43:4229–4361.

Cardinale D, Sandri MT, Colombo A, et al. “Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy.” Circulation. 2004;109:2749–2754.

Kitayama H, Kondo T, Sugiyama J, et al. “High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients.” Breast Cancer. 2017;24:774–782.

Swain SM, Whaley FS, Ewer MS. “Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.” Cancer. 2003;97:2869–2879.

Doroshow JH. “Doxorubicin-induced cardiac toxicity.” N Engl J Med. 1991;324:843–845.

Chow EJ, Chen Y, Kremer LC, et al. “Individual prediction of heart failure among childhood cancer survivors.” J Clin Oncol. 2015;33:394–402.

Qiu S, Zhou T, Qiu B, et al. “Risk factors for anthracycline-induced cardiotoxicity.”. Front Cardiovasc Med. 2021;8:736854.

Zheng H. “It is time to abandon the use of body surface area derived from a 100-year-old formula.” Am J Med. 2022;135:e308–e310.

Armstrong GT, Oeffinger KC, Chen Y, et al. “Modifiable risk factors and major cardiac events among adult survivors of childhood cancer.” J Clin Oncol. 2013;31:3673–3680.

Feijen EAM, Leisenring WM, Stratton KL, et al. “Derivation of anthracycline and anthraquinone equivalence ratios to doxorubicin for late-onset cardiotoxicity.” JAMA Oncol. 2019;5:864–871.

van Dalen EC, Michiels EM, Caron HN, et al. “Different anthracycline derivates for reducing cardiotoxicity in cancer patients.” Cochrane Database Syst Rev. 2010;2010:CD005006.

Smith LA, Cornelius VR, Plummer CJ, et al. “Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials,” BMC Cancer. 2010;10:337.

von Hoff DD, Layard MW, Basa P, et al. “Risk factors for doxorubicin-induced congestive heart failure.” Ann Intern Med. 1979;91:710–717.

Steinherz LJ, Steinherz PG, Tan CT, et al. “Cardiac toxicity 4 to 20 years after completing anthracycline therapy.” JAMA. 1991;266:1672–1677.

Giantris A, Abdurrahman L, Hinkle A, et al. “Anthracycline-induced cardiotoxicity in children and young adults.” Crit Rev Oncol Hematol. 1998;27:53–68.

Eschenhagen T, Force T, Ewer MS, et al. “Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology.” Eur J Heart Fail. 2011;13:1–10.

Cardinale D, Cipolla CM. “Chemotherapy-induced cardiotoxicity: importance of early detection.” Expert Rev Cardiovasc Ther. 2016;14:1297–1299.

Lee KF, Simon H, Chen H, et al. “Requirement for neuregulin receptor erbB2 in neural and cardiac development.” Nature. 1995;378:394–398.

Erickson SL, O'Shea KS, Ghaboosi N, et al. “ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice.” Development. 1997;124:4999–5011.

Gassmann M, Casagranda F, Orioli D, et al. “Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor.” Nature. 1995;378:390–394.

Keefe DL. “Trastuzumab-associated cardiotoxicity.” Cancer. 2002;95:1592–1600.

Nemeth BT, Varga ZV, Wu WJ, et al. “Trastuzumab cardiotoxicity: from clinical trials to experimental studies.” Br J Pharmacol. 2017;174:3727–3748.

Chang HM, Moudgil R, Scarabelli T, et al. “Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1.” J Am Coll Cardiol. 2017;70:2536–2551.

Ewer MS, Vooletich MT, Durand J-B, et al. “Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.” J Clin Oncol. 2005;23:7820–7826.

Fedele C, Riccio G, Malara AE, et al. “Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.” Breast Cancer Res Treat. 2012;134:595–602.

Fuller SJ, Sivarajah K, Sugden PH. “ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium.” J Mol Cell Cardiol. 2008;44:831–854.

Bersell K, Arab S, Haring B, et al. “Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury.” Cell. 2009;138:257–270.

De Keulenaer GW, Doggen K, Lemmens K. “The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy.” Circ Res. 2010;106:35–46.

Ewer MS, Lippman SM. “Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.” J Clin Oncol. 2005;23:2900–2902.

Perez EA, Rodeheffer R. “Clinical cardiac tolerability of trastuzumab.” J Clin Oncol. 2004;22:322–329.

Russell SD, Blackwell KL, Lawrence J, et al. “Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials.” J Clin Oncol. 2010;28:3416–3421.

Slamon DJ, Leyland-Jones B, Shak S, et al. “Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.” N Engl J Med. 2001;344:783–792.

Suter TM, Procter M, van Veldhuisen DJ, et al. “Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.” J Clin Oncol. 2007;25:3859–3865.

Bowles EJ, Wellman R, Feigelson HS, et al. “Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.” J Natl Cancer Inst. 2012;104:1293–1305.

Guenancia C, Lefebvre A, Cardinale D, et al. “Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: a systematic review and meta-analysis.” J Clin Oncol. 2016;34:3157–3165.

Fox KF. “The evaluation of left ventricular function for patients being considered for, or receiving Trastuzumab (Herceptin) therapy.” Br J Cancer. 2006;95:1454.

Liu J, Banchs J, Mousavi N, et al. “Contemporary role of echocardiography for clinical decision making in patients during and after cancer therapy.” JACC Cardiovasc Imaging. 2018;11:1122–1131.

D’Elia N, Caselli S, Kosmala W, et al. “Normal global longitudinal strain: an individual patient meta-analysis.” JACC Cardiovasc Imaging. 2020;13(Pt 1):167–169.

Janet S. “Important Drug Information,” 2016;1−13.

Cai F, Luis MAF, Lin X, et al. “Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: preventive strategies and treatment.” Mol Clin Oncol. 2019;11:15–23.

Rivera E. “Liposomal anthracyclines in metastatic breast cancer: clinical update.” Oncologist. 2003;8(Suppl 2):3–9.

de Baat EC, van Dalen EC, Mulder RL, et al. “Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.” Lancet Child Adolesc Heal. 2022;6:885–894.

Kalam K, Marwick TH. “Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis.” Eur J Cancer. 2013;49:2900–2909.

Guglin M, Krischer J, Tamura R, et al. “Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer.” J Am Coll Cardiol. 2019;73:2859–2868.